Cocrystal Pharma elects Douglas Mayers MD as CMO
M2 - Fri Sep 25, 3:36AM CDT
Bio-pharmaceutical company Cocrystal Pharma (OTC BB:COCP) revealed on Thursday the election of Douglas Mayers MD as its chief medical officer (CMO) to advance its HCV, influenza and norovirus programmes.
Cocrystal Pharma Announces Appointment of Douglas Mayers, M.D., as Chief Medical Officer
Marketwired - Thu Sep 24, 6:00AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a bio-pharmaceutical company dedicated to creating novel small molecules for viral infections and liver diseases, today announced the appointment of Douglas Mayers, M.D., to the position of chief medical officer (CMO). This appointment reflects Cocrystal's continued growth as the Company prepares to advance its HCV, influenza and norovirus programs.
OPK: 8.90 (+0.26)
Cocrystal Pharma names Jeffrey Meckler CEO
M2 - Tue Sep 22, 3:06AM CDT
The board of directors of Cocrystal Pharma (OTCBB:COCP), a bio-pharmaceutical company, disclosed on Monday the addition of Jeffrey Meckler as its chief executive officer (CEO) with effect from 1 October 2015.
Cocrystal Pharma Appoints Jeffrey Meckler as Chief Executive Officer
Marketwired - Mon Sep 21, 7:02AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a bio-pharmaceutical company focused on developing novel antiviral therapeutics for human diseases, today announced that its Board of Directors has appointed board member Jeffrey Meckler to the position of Chief Executive Officer (CEO), effective October 1st. Mr. Meckler had been serving as Cocrystal Pharma's Interim CEO since March 31, 2015.
Nasopharyngitis (Common Cold) Pipeline Review, H2 2015 - 5 Companies & 11 Drug Profiles
M2 - Fri Sep 04, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jrkmc3/nasopharyngitis) has announced the addition of the "Nasopharyngitis (Common Cold) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Charleston Laboratories, Inc. - Cocrystal Pharma, Inc. - Neos Therapeutics, Inc. - Orbis Biosciences, Inc. - Vernalis Plc Drug Profiles - (chlorpheniramine maleate codeine) - Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - CCP-05 - CCP-06 - CCP-07 - CCP-08 - CLAT-313 - guaifenesin ER - Small Molecule for Cough and Cold - Small Molecule to Inhibit MAPK13 for Asthma and Cold - Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold For more information visit http://www.researchandmarkets.com/research/jr...haryngitis
NEOS: 18.69 (-0.57)
H5N1 Infection (Avian Influenza) Pipeline Review 2015 - 42 Companies & 59 Drug Profiles
M2 - Fri Jul 31, 10:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/spx39q/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Akshaya Bio Inc. - AlphaVax, Inc. - Antigen Express, Inc. - Aphios Corporation - Aprogen, Inc. - BioDiem Ltd - CEL-SCI Corporation - Cocrystal Pharma, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Gemmus Pharma Inc. - GlaxoSmithKline Plc - Green Cross Corporation - Hemispherx Biopharma, Inc. - iBio, Inc. - Immunovaccine, Inc. - Inovio Pharmaceuticals, Inc. - Johnson & Johnson - Kineta, Inc. - Medicago Inc. - Medigen Biotechnology Corporation - Microgen Scientific Industrial Company for Immunobiological Medicines - Myelo Therapeutics GmbH - NanoBio Corporation - Nanotherapeutics, Inc. - NanoViricides, Inc. - NewLink Genetics Corporation - Novartis AG - OPKO Health, Inc. - PaxVax - PDS Biotechnology Corporation - PeptiDream Inc. - Protein Sciences Corporation - REPLICor Inc. - SIGA Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/sp..._infection
JNJ: 95.37 (+0.29), INO: 6.16 (+0.20), EBS: 30.49 (+0.77), CVM: 0.72 (-0.02), OPK: 8.90 (+0.26), NLNK: 34.31 (+1.42), IBIO: 0.68 (unch), NNVC: 1.35 (-0.05), GSK: 40.22 (+0.06), NVS: 91.90 (-0.71)
IDI Management Fires Back Against Blog Post
at The Street - Wed Jul 22, 11:32AM CDT
Executives say investor Philip Frost supports them and the company.
YHOO: 32.52 (+0.15), IDI: 7.17 (-0.10), EFX: 105.48 (+0.78)
Cocrystal Pharma Names Walt Addison Linscott, Esq. New General Counsel and Corporate Secretary
Marketwired - Wed Jul 15, 8:25AM CDT
Cocrystal Pharma, Inc. (OTCQB:COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today the appointment of Walt Addison Linscott, Esq. as General Counsel and Corporate Secretary.
ABT: 41.89 (+0.73)
Cocrystal Pharma to Present at Jefferies 2015 Global Healthcare Conference
Marketwired - Thu May 28, 8:27AM CDT
Cocrystal Pharma, Inc. (OTCQB: COCP), a company focused on developing novel antiviral therapeutics for human diseases, announced today that it will be presenting at the Jefferies 2015 Global Healthcare Conference on Thursday, June 4, 2015 from 12:30 p.m. to 1:00 p.m. at the Grand Hyatt in New York, New York.
Global Hepatitis C Pipeline Report 2015 - 103 Companies & 251 Drug Profiles
M2 - Wed May 20, 4:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/96rn9k/hepatitis_c) has announced the addition of the "Hepatitis C - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 30 of the 100 Companies - 3-V Biosciences, Inc. - AbbVie Inc. - Achillion Pharmaceuticals, Inc. - Adaptimmune Limited - AiCuris GmbH & Co. KG - AIMM Therapeutics B.V. - Akshaya Bio Inc. - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amarna Therapeutics B.V. - American Gene Technologies International Inc. - Anacor Pharmaceuticals, Inc. - ARA Healthcare Pvt. Ltd. - Arrowhead Research Corporation - Ascendis Pharma A/S - Astex Pharmaceuticals, Inc. - Biogenomics Limited - BioLineRx, Ltd. - Bionor Pharma ASA - Biotest AG - Biotron Limited - Bolder Biotechnology, Inc. - Bristol-Myers Squibb Company - Celgene Corporation - Chiasma, Inc. - Chugai Pharmaceutical Co., Ltd. - Cocrystal Pharma, Inc. - Conatus Pharmaceuticals Inc. - Crucell N.V. - Debiopharm International S.A. For more information visit http://www.researchandmarkets.com/research/96...epatitis_c
ASND: 17.24 (+0.05), ARWR: 5.89 (+0.13), ACHN: 7.57 (-0.10), CNAT: 4.21 (-0.06), ANAC: 115.06 (+2.13), ABBV: 55.64 (-0.40), BMY: 61.44 (+0.93), CELGZ: 1.74 (+0.04)
Solid Pipeline and Big Player Backing: Cocrystal Pharma Analyst Report Issued by BrokerBank Securities, Inc.
PR Newswire - Mon Apr 27, 6:00AM CDT
Cocrystal Pharma Inc. (OTCQB: COCP) a Washington-State based pharmaceutical company working to develop antiviral therapeutics as treatments for serious and/or chronic viral diseases, expects to begin clinical studies on several of its antiviral therapeutic treatments in 2015. The company has several drugs in various stages of development for the treatment of Hepatitis C, Influenza, Norovirus, Dengue Fever and others.
InsiderInsights.com Daily Round Up 4/23/15: GE, OMN, COCP, AGCO
InsiderInsights - at Seeking Alpha - Fri Apr 24, 7:53AM CDT
STFC: 24.13 (-0.01), GE: 28.07 (+0.04), OMN: 6.60 (+0.01), AGCO: 47.01 (-0.57), SAM: 228.44 (+2.75), AMGN: 149.59 (-0.31), ILMN: 147.77 (+7.40), NXRT: 13.52 (-0.07), BDCV: 4.68 (-0.01), MPWR: 54.99 (-0.31), WCIC: 23.25 (-0.29), ADS: 280.12 (+0.71), KMX: 58.77 (-1.19), SVVC: 8.55 (+0.10), ALNY: 83.16 (+0.88), GRPN: 3.87 (+0.01), UCTT: 5.82 (-0.06)
Cocrystal Pharma - Overhyped Biotech Or The Next Pharmasset?
Greg Buch - at Seeking Alpha - Tue Apr 07, 10:19AM CDT
Opko and its CEO Dr. Phillip Frost Add MabVax to Their Portfolios
ACCESSWIRE - Mon Apr 06, 6:15PM CDT
CORAL GABLES, FL / ACCESSWIRE / April 6, 2015 / Holding companies invest in the securities of other companies all the time aiming to increase shareholder value. There are hits and there are misses, as with all investments. But Opko Health (NYSE: OPK) has been on such a hot streak in this game especially in the last few months that even relatively small deals deserve attention. Its latest move - both for Opko and for Frost's personal investment trust - is to be part of a $12M private placement into MabVax Therapeutics (OTCQB: MBVX).
OPK: 8.90 (+0.26), PFE: 33.24 (+0.15), JUNO: 48.64 (+0.84), NVCN: 4.24 (+0.18)
InsiderInsights.com Daily Round Up 3/27/15: COCP, GPRO, SJW, AGCO
InsiderInsights - at Seeking Alpha - Sun Mar 29, 12:55PM CDT
GPRO: 29.08 (+1.48), HCOM: 22.59 (+0.32), DPLO: 26.65 (+1.93), AGCO: 47.01 (-0.57), ENV: 32.74 (+0.16), LPI: 13.40 (-0.56), GOOG: 643.61 (+4.45), NOW: 74.42 (+1.40), ARMK: 30.89 (-0.03), JAZZ: 133.40 (+0.37), GLF: 8.79 (+0.43), SJW: 32.00 (-0.44), JGW: 5.77 (-0.10), ALCO: 43.48 (+0.32), FI: 17.90 (+0.22), CRM: 75.25 (+0.16)
Opko's Frost Inks Levon Deal with Israel's SciVac, a Hint for the Next Merger?
ACCESSWIRE - Fri Mar 20, 10:30AM CDT
NEW YORK, NY / ACCESSWIRE / March 20, 2015 / On September 11 last year, a little-known Israeli financial magazine called Globes came out with a report that Dr. Phillip Frost, Chairman and CEO of Opko Health (NYSE:OPK), and then Chairman of Teva Pharmaceuticals (NYSE:TEVA), was interested in moving a private Israeli biotech called SciVac, 45% owned by Opko, into a corporate shell and making it public.
OPK: 8.90 (+0.26), TEVA: 58.96 (-0.28)